What procedures can I expect during visits?

During study visits, you will have tests and complete questionnaires to monitor your health and CIDP symptoms. Most of the visits will take 3 hours, but a few may take up to 10 hours as you will not have every test at every visit.

- ✓ Consent
- ✓ Health & treatment review
- ✓ Blood and urine samples
- ✓ Vitals, physical exams, neurological exams
- ✓ Electrocardiogram heart test
- ✓ Questionnaires
- ✓ CIDP tests
- ✓ If applicable, pregnancy tests and vaccines

Dianthus Therapeutics

DNTH103-CIDP-301 Patient Brochure
21-May-2025 V1.0

Thank you for considering the CAPTIVATE study

If you qualify and consent for the study, you will receive study-related treatment, tests, and doctor visits at no cost to you.

Being in a study is completely voluntary. If you decide to join the study and then change your mind, you can leave at any time. Although your condition may or may not improve during the study, you would be helping to find better way to treat CIDP.

If you re interested in learning more, please contact us. We are happy to answer questions you may have.

clinicaltrials@dianthustx.com

CAPTIVATE

Clinical Trial

A research study for people with chronic inflammatory demyelinating polyneuropathy

Where regulations permit:

- Transportation support and reimbursement are available for patients and caregivers
- Some visits may be conducted at home

What is CIDP?

CIDP is a condition where the body's immune system mistakenly attacks and damages the protective covering around your nerves. This can cause:

- Weakness, numbness, pain, and tingling sensations in your arms and legs
- Problems with balance and walking

What is the purpose of this study?

To understand if the study medication, DNTH103, works as a new treatment for your CIDP.

Who can join the study?

You may be able to join the study if you are between 18 and 75 years old, meet all study criteria, and have one of these treatment experiences:

- Currently using standard CIDP treatments like immunoglobulins (Igs) or steroids, and have seen improvement
- Previously responded to standard CIDP treatments but are no longer receiving them for various reasons (such as access issues)
- Did not improve with standard CIDP treatments despite trying them for at least 12 weeks
- Couldn't tolerate standard CIDP treatment due to side effects
- Have never received treatment for CIDP

What is the study treatment?

During Part A, the study treatment will be DNTH103. If your symptoms improve in Part A, you will move to Part B where the study treatment could be DNTH103 or placebo. The 1st treatment with DNTH103 will be administered into your vein using a needle. All remaining treatments will be injected under your skin every 2 weeks. Neither you nor the study doctor and staff will know which study treatment you are getting during Part B.

Study medicine

Not currently approved by the health authority for treating CIDP but can be used for research purposes.

Placebo

Looks like the study medicine but does not contain any active medicine. Helps researchers understand the true impact of the study medicine.

DNTH103 works by blocking activated C1s proteins. Activated C1s proteins can trigger inflammation that damages protective covering of your nerves. By only blocking this specific protein, DNTH103 aims to reduce nerve damage while allowing other parts of your immune system to continue working normally.

What happens during the study?

The study has 5 parts. If you participate in all parts, you will be in the study for up to 4 years. For your safety and well-being, if DNTH103 doesn't improve your CIDP in Part A, you'll move to the safety follow-up without placebo exposure.

Screening

At least 1 visit for qualifying tests.

You may need to lower steroid dose and keep this lower dose during the study.

Treatment Part A

Up to 9 visits over 15 wks.

You'll get **DNTH103** and visit the study clinic **every 2 weeks.** If you're on Igs, 1st DNTH103 dose will **be 1 week after your last Ig treatment.**

Treatment Part B

Up to 28 visits over 53 wks.

You'll get **DNTH103 or Placebo** and visit the study clinic **every 2 weeks.** You may be able to join the open-label extension (OLE).

Treatment OLE

Up to 53 visits over 103 wks.

You'll get **DNTH103 and** visit the study clinic **every 2 weeks.** Starting on wk. 18, some visits may be conducted at home.

Safety Follow-up

Up to 6 visits over 40 wks.

You will not get study treatment. You'll return to standard CIDP treatment.